ES2563034T3 - Procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol e hidratos del mismo, e intermedios para la producción de los mismos - Google Patents
Procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol e hidratos del mismo, e intermedios para la producción de los mismos Download PDFInfo
- Publication number
- ES2563034T3 ES2563034T3 ES05790615.8T ES05790615T ES2563034T3 ES 2563034 T3 ES2563034 T3 ES 2563034T3 ES 05790615 T ES05790615 T ES 05790615T ES 2563034 T3 ES2563034 T3 ES 2563034T3
- Authority
- ES
- Spain
- Prior art keywords
- benzyloxyphenylthio
- ethyl
- chlorophenyl
- mixture
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
- C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/02—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
- C07C319/12—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols by reactions not involving the formation of mercapto groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/01—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton
- C07C323/02—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton having sulfur atoms of thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/07—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton having sulfur atoms of thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3- propanodiol o un hidrato del mismo, que comprende las etapas de: hacer reaccionar el 4-(3-benciloxifeniltio)-2-clorobenzaldehído con dietilfosfonoacetato de etilo en un disolvente en presencia de una base para formar el 3-[4-(3-benciloxifeniltio)-2-clorofenil]acrilato de etilo; reducir el 3-[4-(3-benciloxifeniltio)-2-clorofenil]acrilato de etilo resultante, seguido de la mesilación, yodación y nitración, para formar el 1-benciloxi-3-[3-cloro-4-(3-nitropropil)feniltio]benceno; hidroximetilar el 1-benciloxi-3-[3-cloro-4-(3-nitropropil)feniltio]benceno resultante con formaldehído para formar el 2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-2-nitro-1,3-propanodiol; y reducir el 2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-2-nitro-1,3-propanodiol resultante para formar el producto deseado.
Description
5
10
15
20
25
30
35
40
45
50
El sólido cristalizado se recogió por filtración y se lavó con acetona acuosa al 40% (461 ml) (temperatura interna = 4 °C). El producto lavado se secó durante 50 min en una corriente de aire y posteriormente se secó al aire a temperatura ambiente. El producto se secó otras 8 horas más a 38 °C en una corriente de aire. Esto dio el compuesto (3) como cristales granulares de color amarillo pálido (136 g, 320 mmol, rendimiento del 98%).
TF 45-47 °C (método de placa calefactora).
EI-MS m/z: 424 (M+).
1H-RMN (CDCl3, 400 MHz) δ: 1,34 (3H, t, J = 7,1 Hz), 4,27 (2H, q, J = 7,1 Hz), 5,05 (2H, s), 6,38 (1H, d, J = 16,1 Hz), 6,92-7,11 (4H, m), 7,23-7,49 (8H, m), 8,02 (1H, d, J = 15,9 Hz).
Ejemplo 2
1-Benciloxi-3-[3-cloro-4-(3-nitropropil)feniltio]benceno (8)
Se añadieron tetrahidrofurano (THF) (405 ml) y etanol (405 ml) al 3-[4-(3-benciloxifeniltio)-2-clorofenil]acrilato de etilo
(3) (135 g, 318 mmol). Mientras la mezcla se agitaba a una temperatura interna de 35 °C, se le añadió tricloruro de bismuto (25,0 g, 79,4 mmol) seguido de la adición lenta de borohidruro de sodio (15,0 g, 397 mmol). La mezcla se siguió agitando mientras se enfriaba y se le añadió lentamente más borohidruro de sodio (15,0 g, 397 mmol). La mezcla se siguió agitando mientras que se estaba enfriando. Se le añadió más tricloruro de bismuto (5,01 g, 15,9 mmol) a continuación a una temperatura interna de 40 °C, seguido de la adición de borohidruro de sodio (6,01 g, 159 mmol) y se agitó durante 55 min a una temperatura interna de 40 a 46 °C.
Mientras la mezcla de reacción se enfriaba y agitaba, se le añadió acetona (41 ml) a una temperatura interna de 10 °C y la mezcla se agitó durante 5 min. A esto le siguió la adición de 810 ml de ácido clorhídrico a 1 mol/l ajustado a pH 1 y de acetato de etilo (675 ml), y se agitó durante 30 min.
El sólido negro resultante en la mezcla de reacción se separó por filtración y se lavó con acetato de etilo (135 ml). La capa orgánica se separó y se recogió, y se lavó secuencialmente con ácido clorhídrico a 0,1 mol/l (405 ml), una solución acuosa de bicarbonato de sodio al 5% (405 ml) y solución salina al 28% (405 ml).
La capa orgánica se concentró a presión reducida y se secó a una temperatura externa de 50 °C durante 30 min para dar el 3-[4-(3-benciloxifeniltio)-2-clorofenil]propionato de etilo (4) como un aceite amarillo pálido (132 g, equivalente a 318 mmol). Sin purificar, el compuesto (4) se disolvió en tetrahidrofurano (THF) (949 ml). Mientras la mezcla se estaba agitando, se le añadieron borohidruro de potasio (22,3 g, 413 mmol) y a continuación cloruro de litio (17,5 g, 413 mmol) a una temperatura interna de 20 °C y la mezcla se agitó durante 20 min.
Posteriormente, se le añadió etanol (47,5 ml) y la mezcla se agitó durante 1 hora a una temperatura interna de 30 a 33 °C y a continuación durante 40 min más a una temperatura interna de 44 a 45 °C. Se le añadió entonces etanol (23,7 ml) y la mezcla se agitó durante 30 min más a una temperatura interna de 43 a 45 °C para completar la reacción. Mientras la mezcla de reacción se enfriaba y agitaba, se le añadieron acetona (71,2 ml) y a continuación agua (475 ml), y la mezcla se agitó durante 1 hora mientras se estaba enfriando. Posteriormente se le añadieron ácido clorhídrico a 2 mol/l (217 ml, 434 mmol) y a continuación acetato de etilo (475 ml) a una temperatura interna de 26 °C, y la mezcla se siguió agitando.
La capa orgánica se separó y se recogió, y se lavó secuencialmente con una solución acuosa de bicarbonato de sodio al 5% (475 ml) y solución salina al 28% (475 ml). A continuación, la capa orgánica se concentró a presión reducida y se secó a una temperatura externa de 50 °C a presión reducida durante 1 hora. Esto dio el 3-[4-(3benciloxifeniltio)-2-clorofenil]propanol (5) (124 g, equivalente a 318 mmol) como un aceite amarillo pálido.
Sin purificar, el compuesto (5) se disolvió en acetato de etilo (1,22 l). Se le añadió trietilamina (64,3 g, 635 mmol) y, mientras la mezcla se enfriaba y agitaba, se le añadió lentamente cloruro de metanosulfonilo (54,6 g, 477 mmol) gota a gota a una temperatura interna de 6 a 15 °C. La mezcla se agitó a continuación durante 1 hora a una temperatura interna de 5 a 15 °C. Posteriormente se le añadió agua del grifo (1,22 l) y la mezcla se agitó durante 20 min. A continuación se le añadió ácido clorhídrico a 6 mol/l (26,3 ml, 158 mmol), y se separó y se recogió la capa orgánica.
La capa orgánica se lavó secuencialmente con una solución acuosa de sulfato de sodio al 2% (1,22 l) y una solución acuosa de sulfato de sodio al 30% (612 ml). A continuación, la capa orgánica se concentró a presión reducida y el concentrado se secó a presión reducida a una temperatura externa de 50 °C durante 1 hora. Esto dio el metanosulfonato de 3-[4-(3-benciloxifeniltio)-2-clorofenil]propilo (6) como un aceite amarillo pálido (150 g, equivalente a 318 mmol). Sin purificar, el compuesto (6) se disolvió en acetato de etilo (441 ml) y DMF (441 ml). Mientras la mezcla se estaba agitando, se le añadió yoduro de sodio (61,9 g, 413 mmol) y la mezcla se agitó a una temperatura interna de 62 a 65 °C durante 3 horas. Mientras la mezcla se enfriaba y se agitaba, se le añadieron una solución acuosa de sulfato de sodio al 8% (1,32 l) y acetato de etilo (882 ml) a una temperatura interna de 30 °C. Se separó la capa orgánica y se recogió.
7
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004297651 | 2004-10-12 | ||
JP2004297651 | 2004-10-12 | ||
PCT/JP2005/018602 WO2006041019A1 (ja) | 2004-10-12 | 2005-10-07 | 2-アミノ-2-[2-[4-(3-ベンジルオキシフェニルチオ)-2-クロロフェニル]エチル]-1,3-プロパンジオール塩酸塩又はその水和物の製造方法及びその製造中間体 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2563034T3 true ES2563034T3 (es) | 2016-03-10 |
Family
ID=36148313
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES05790615.8T Active ES2563034T3 (es) | 2004-10-12 | 2005-10-07 | Procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol e hidratos del mismo, e intermedios para la producción de los mismos |
ES12167175.4T Active ES2615498T3 (es) | 2004-10-12 | 2005-10-07 | Procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12167175.4T Active ES2615498T3 (es) | 2004-10-12 | 2005-10-07 | Procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol |
Country Status (14)
Country | Link |
---|---|
US (1) | US7795472B2 (es) |
EP (2) | EP2511262B1 (es) |
JP (1) | JP4792400B2 (es) |
KR (1) | KR101181090B1 (es) |
CN (2) | CN101072752B (es) |
AU (1) | AU2005292984B2 (es) |
BR (1) | BRPI0516337A (es) |
CA (1) | CA2583846C (es) |
ES (2) | ES2563034T3 (es) |
MX (1) | MX2007004319A (es) |
PL (2) | PL1806338T3 (es) |
PT (1) | PT2511262T (es) |
RU (1) | RU2376285C2 (es) |
WO (1) | WO2006041019A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101905023B (zh) * | 2004-07-16 | 2012-07-11 | 杏林制药株式会社 | 有效的医药使用方法及与副作用发生的防御相关的方法 |
US7795472B2 (en) | 2004-10-12 | 2010-09-14 | Kyorin Pharmaceutical Co., Ltd. | Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride and hydrates thereof, and intermediates in the production thereof |
US8048928B2 (en) * | 2005-10-07 | 2011-11-01 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent for treating liver disease containing 2-amino-1,3-propanediol derivative as active ingredient, and method for treating liver disease |
TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
NZ574011A (en) * | 2006-08-08 | 2011-10-28 | Kyorin Seiyaku Kk | Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient |
SG174029A1 (en) * | 2006-08-08 | 2011-09-29 | Kyorin Seiyaku Kk | Aminoalcohol derivative and immunosuppressant containing the same as active ingredient |
JP5153648B2 (ja) * | 2006-12-22 | 2013-02-27 | 住友精化株式会社 | 3−ベンジルオキシベンゼンチオールの製造方法 |
WO2009099174A1 (ja) | 2008-02-07 | 2009-08-13 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤 |
CN106366027A (zh) | 2008-03-24 | 2017-02-01 | 杏林制药株式会社 | 2‑氨基‑2‑[2‑[4‑(3‑苄氧基苯硫基)‑2‑氯苯基]乙基]‑1,3‑丙二醇盐酸盐的结晶化方法 |
CN102099331A (zh) * | 2008-05-19 | 2011-06-15 | 杏林制药株式会社 | 光学活性氨基醇衍生物的制备方法 |
JP5330066B2 (ja) * | 2009-04-13 | 2013-10-30 | 富士フイルム株式会社 | トリアリールアミン化合物の製造方法 |
WO2012073249A1 (en) | 2010-12-01 | 2012-06-07 | Arch Pharmalabs Limited | A novel process for the preparation of 3-(benzyloxy)- benzenethiol, a key intermediate for the preparation of pharmaceutical drugs. |
TWI554493B (zh) * | 2012-04-18 | 2016-10-21 | Kyorin Seiyaku Kk | Crystallization of 4- (3-benzyloxyphenylthio) -2-chloro-1- (3-nitropropyl) benzene |
CN102718662A (zh) * | 2012-07-12 | 2012-10-10 | 杭州新博思生物医药有限公司 | 一种制备盐酸西那卡塞的方法 |
CN103113270A (zh) * | 2012-11-26 | 2013-05-22 | 盛世泰科生物医药技术(苏州)有限公司 | 一种4-(3-苄氧基-苯基硫烷基)-2-氯-1-乙烯基苯的合成方法 |
CN108017928A (zh) * | 2017-12-15 | 2018-05-11 | 淮海工学院 | 一种用于生物分子标记的聚乙二醇化吲哚菁染料及其制备方法 |
CA3106608A1 (en) | 2018-07-27 | 2020-01-30 | Priothera Limited | Preparation for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation |
AU2021424131A1 (en) | 2021-01-28 | 2023-07-27 | Priothera Limited | Methods of treatment with s1p receptor modulators |
EP4248958A3 (en) | 2021-01-28 | 2024-01-03 | Priothera SAS | Methods of treatment with s1p receptor modulators |
WO2023156506A1 (en) | 2022-02-16 | 2023-08-24 | Priothera Sas | Methods of treatment with car cells in combination with s1p receptor modulators |
EP4282407A1 (en) | 2022-05-27 | 2023-11-29 | Priothera SAS | Treatment of cancer with s1p receptor agonists |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0627406B1 (en) | 1992-10-21 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
US5475138A (en) * | 1994-07-07 | 1995-12-12 | Pharm-Eco Laboratories Incorporated | Method preparing amino acid-derived diaminopropanols |
US5948820A (en) | 1994-08-22 | 1999-09-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzene compound and pharmaceutical use thereof |
US5447922A (en) | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
KR100551931B1 (ko) | 1997-04-04 | 2006-02-16 | 미츠비시 웰파마 가부시키가이샤 | 2-아미노프로판-1,3-디올 화합물, 이것의 의약으로서의 용도 및 합성 중간체 |
JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
CA2336412C (en) | 1998-07-02 | 2007-11-27 | Junichi Shimada | Medicament for treatment of diabetes |
AU767241B2 (en) | 1998-09-14 | 2003-11-06 | Qiang Xu | Immunosuppressive agents |
US20020143034A1 (en) | 1998-12-30 | 2002-10-03 | Fujisawa Pharmaceutical Co. Ltd. | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
AU2001264313A1 (en) | 2000-06-20 | 2002-01-02 | Japan Tobacco Inc. | Pyrazolopyridine compounds and use thereof as drugs |
CN1328387C (zh) | 2000-07-13 | 2007-07-25 | 三共株式会社 | 氨基醇衍生物 |
JP2002053575A (ja) | 2000-08-09 | 2002-02-19 | Sankyo Co Ltd | アミノアルコ−ル類 |
AU2001285331B2 (en) | 2000-08-31 | 2006-04-06 | Merck & Co., Inc. | Phosphate derivatives as immunoregulatory agents |
WO2002064616A2 (en) | 2001-01-30 | 2002-08-22 | University Of Virgina Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
WO2002062389A1 (fr) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa |
WO2002067915A1 (en) | 2001-02-22 | 2002-09-06 | Novartis Ag | Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function |
WO2002076995A2 (en) | 2001-03-26 | 2002-10-03 | Novartis Ag | 2-amino-propanol derivatives |
JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
US7179817B2 (en) | 2001-05-10 | 2007-02-20 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
JP2004534772A (ja) | 2001-05-24 | 2004-11-18 | 藤沢薬品工業株式会社 | アミノアルコール誘導体 |
JPWO2003020313A1 (ja) | 2001-09-04 | 2004-12-16 | 小野薬品工業株式会社 | スフィンゴシン−1−リン酸受容体調節剤からなる呼吸器疾患治療剤 |
ATE463478T1 (de) | 2001-09-27 | 2010-04-15 | Kyorin Seiyaku Kk | Diaryletherderivat, dessen additionssalz und immunosuppressivum |
EP1431284B1 (en) | 2001-09-27 | 2007-11-21 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivative, addition salt thereof, and immunosuppressant |
JP4035759B2 (ja) | 2001-11-06 | 2008-01-23 | 独立行政法人産業技術総合研究所 | アミノアルコールリン酸化合物、製造方法、及びその利用方法 |
JP2003267936A (ja) | 2002-01-11 | 2003-09-25 | Sankyo Co Ltd | ベンゼン環化合物 |
NZ533994A (en) | 2002-01-11 | 2006-10-27 | Sankyo Co | Amino alcohol derivative or phosphonic acid derivative and medicinal compostion containing these |
WO2003062248A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
AU2003207567B2 (en) | 2002-01-18 | 2008-01-24 | Merck Sharp & Dohme Corp. | Edg receptor agonists |
US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
WO2003073986A2 (en) | 2002-03-01 | 2003-09-12 | Merck & Co., Inc. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
WO2003074008A2 (en) | 2002-03-01 | 2003-09-12 | Merck & Co., Inc. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
EP2963017A1 (en) * | 2002-03-11 | 2016-01-06 | Molecular Insight Pharmaceuticals, Inc. | Technetium-dipyridine complexes, and methods of use thereof |
JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Edg受容体アゴニストとしての1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)アゼチジン−3−カルボキシラートおよび1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)ピロリジン−3−カルボキシラート |
US8765783B2 (en) | 2002-06-26 | 2014-07-01 | Ono Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation |
WO2004010949A2 (en) | 2002-07-30 | 2004-02-05 | University Of Virginia Patent Foundation | Compounds active in spinigosine 1-phosphate signaling |
JP4166218B2 (ja) | 2002-09-13 | 2008-10-15 | ノバルティス アクチエンゲゼルシャフト | アミノ−プロパノール誘導体 |
AU2003264430B2 (en) * | 2002-09-19 | 2009-03-19 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative, addition salt thereof, and immunosuppressant |
US20060046979A1 (en) | 2002-09-24 | 2006-03-02 | Foster Carolyn A | Organic compounds |
EP1553075B1 (en) | 2002-10-03 | 2013-08-14 | Ono Pharmaceutical Co., Ltd. | Lpa receptor antagonists |
JP4140698B2 (ja) | 2002-10-18 | 2008-08-27 | 第一三共株式会社 | リン酸又はホスホン酸誘導体 |
US7220734B2 (en) | 2002-12-20 | 2007-05-22 | Merck & Co., Inc. | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists |
ES2393551T3 (es) | 2003-02-11 | 2012-12-26 | Irm Llc | Compuestos bicíclicos novedosos y composiciones |
BRPI0407658A (pt) | 2003-02-18 | 2006-02-21 | Kyorin Seiyaku Kk | derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico |
JP2004307441A (ja) | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | ベンゼン誘導体とその付加塩及び免疫抑制剤 |
JP2004307442A (ja) | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | ヘテロ環誘導体とその付加塩及び免疫抑制剤 |
JP2004307439A (ja) | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | アミノジオール誘導体とその付加塩及び免疫抑制剤 |
JP2004307440A (ja) | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | 2−アミノ‐1,3‐プロパンジオール誘導体とその付加塩 |
ATE547395T1 (de) | 2003-04-30 | 2012-03-15 | Novartis Pharma Gmbh | Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors |
AU2004234067B2 (en) | 2003-04-30 | 2008-02-28 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
EP1625123A4 (en) | 2003-05-15 | 2007-08-29 | Merck & Co Inc | 3- (2-AMINO-1-AZACYCLYL) -5-ARYL-1,2,4-OXADIAZOLE AS S1P RECEPTOR AGONISTS |
WO2004103309A2 (en) | 2003-05-19 | 2004-12-02 | Irm Llc | Immunosuppressant compounds and compositions |
GB0313612D0 (en) | 2003-06-12 | 2003-07-16 | Novartis Ag | Organic compounds |
JP2005047899A (ja) | 2003-07-11 | 2005-02-24 | Sankyo Co Ltd | アミノアルコール化合物 |
TW200505416A (en) | 2003-08-12 | 2005-02-16 | Mitsubishi Pharma Corp | Bi-aryl compound having immunosuppressive activity |
WO2005014603A1 (en) | 2003-08-12 | 2005-02-17 | Mitsubishi Pharma Corporation | Phosphinane compounds with immunomodulating activity |
AU2004268052B2 (en) | 2003-08-28 | 2009-11-19 | Novartis Ag | Aminopropanol derivatives |
US7825109B2 (en) | 2003-08-29 | 2010-11-02 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding S1P receptor and pharmaceutical use thereof |
CA2539438A1 (en) | 2003-10-01 | 2005-04-14 | Merck And Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
GB0324210D0 (en) | 2003-10-15 | 2003-11-19 | Novartis Ag | Organic compounds |
WO2005041899A2 (en) | 2003-11-03 | 2005-05-12 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
CN1894225A (zh) | 2003-12-17 | 2007-01-10 | 默克公司 | 作为鞘氨醇1-磷酸(内皮分化基因)受体激动剂的(3,4-二取代)丙酸酯 |
TW200526548A (en) | 2003-12-25 | 2005-08-16 | Sankyo Co | Ether derivatives |
GB0401332D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
CA2553572A1 (en) | 2004-02-24 | 2005-09-09 | Irm Llc | Immunosuppressant compounds and compositions |
AU2005215320B2 (en) | 2004-02-24 | 2008-04-17 | Sankyo Company, Limited | Amino alcohol compound |
JP2005247691A (ja) | 2004-03-01 | 2005-09-15 | Toa Eiyo Ltd | S1p3受容体拮抗薬 |
GB0405289D0 (en) | 2004-03-09 | 2004-04-21 | Novartis Ag | Organic compounds |
GB0411929D0 (en) | 2004-05-27 | 2004-06-30 | Novartis Ag | Organic compounds |
JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
CN101905023B (zh) | 2004-07-16 | 2012-07-11 | 杏林制药株式会社 | 有效的医药使用方法及与副作用发生的防御相关的方法 |
TW200611687A (en) | 2004-07-29 | 2006-04-16 | Sankyo Co | Pharmaceutical compositions used for immunosuppressant |
EP1781595A1 (en) | 2004-08-13 | 2007-05-09 | Praecis Pharmaceuticals Inc. | Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity |
JPWO2006041015A1 (ja) | 2004-10-12 | 2008-05-15 | 杏林製薬株式会社 | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
US7795472B2 (en) | 2004-10-12 | 2010-09-14 | Kyorin Pharmaceutical Co., Ltd. | Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride and hydrates thereof, and intermediates in the production thereof |
MX2007006706A (es) | 2004-12-06 | 2007-10-18 | Univ Virginia | Analogos de esfingosina 1-fosfato amida de arilo. |
TW200702326A (en) | 2005-05-31 | 2007-01-16 | Mitsubishi Pharma Corp | 2-aminobutanol compound and its pharmaceutical use |
TWI418350B (zh) | 2005-06-24 | 2013-12-11 | Sankyo Co | 含有ppar調節劑之醫藥組成物的用途 |
KR101476591B1 (ko) | 2005-09-09 | 2014-12-24 | 노파르티스 아게 | 자가면역성 질환의 치료 |
US8048928B2 (en) | 2005-10-07 | 2011-11-01 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent for treating liver disease containing 2-amino-1,3-propanediol derivative as active ingredient, and method for treating liver disease |
CN101282926B (zh) | 2005-10-12 | 2011-07-13 | 东亚荣养株式会社 | S1p3受体拮抗剂 |
TWI389683B (zh) | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
US20070264403A1 (en) * | 2006-05-11 | 2007-11-15 | Nehmer Warren L | Sparkling agglomerated sweetener, and method of making it |
CN101505744A (zh) | 2006-07-25 | 2009-08-12 | 爱尔康研究有限公司 | 用于预防和治疗眼部病症的内皮分化基因亚家庭3(edg-3,s1p3)受体的拮抗剂 |
US7877152B2 (en) | 2006-07-31 | 2011-01-25 | JusJas LLC | Bipolar stimulation/recording device with widely spaced electrodes |
-
2005
- 2005-10-07 US US11/665,058 patent/US7795472B2/en not_active Expired - Fee Related
- 2005-10-07 BR BRPI0516337-4A patent/BRPI0516337A/pt not_active IP Right Cessation
- 2005-10-07 ES ES05790615.8T patent/ES2563034T3/es active Active
- 2005-10-07 RU RU2007117372/04A patent/RU2376285C2/ru not_active IP Right Cessation
- 2005-10-07 PT PT121671754T patent/PT2511262T/pt unknown
- 2005-10-07 KR KR1020077010572A patent/KR101181090B1/ko active IP Right Grant
- 2005-10-07 CN CN2005800417574A patent/CN101072752B/zh not_active Expired - Fee Related
- 2005-10-07 EP EP12167175.4A patent/EP2511262B1/en not_active Not-in-force
- 2005-10-07 AU AU2005292984A patent/AU2005292984B2/en not_active Ceased
- 2005-10-07 CA CA2583846A patent/CA2583846C/en active Active
- 2005-10-07 EP EP05790615.8A patent/EP1806338B1/en not_active Not-in-force
- 2005-10-07 PL PL05790615T patent/PL1806338T3/pl unknown
- 2005-10-07 PL PL12167175T patent/PL2511262T3/pl unknown
- 2005-10-07 WO PCT/JP2005/018602 patent/WO2006041019A1/ja active Application Filing
- 2005-10-07 MX MX2007004319A patent/MX2007004319A/es active IP Right Grant
- 2005-10-07 JP JP2006540913A patent/JP4792400B2/ja not_active Expired - Fee Related
- 2005-10-07 ES ES12167175.4T patent/ES2615498T3/es active Active
- 2005-10-07 CN CN2010101975227A patent/CN101880250B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1806338A4 (en) | 2009-12-16 |
CN101072752B (zh) | 2010-12-08 |
MX2007004319A (es) | 2007-06-15 |
US7795472B2 (en) | 2010-09-14 |
JP4792400B2 (ja) | 2011-10-12 |
PL2511262T3 (pl) | 2017-08-31 |
CA2583846C (en) | 2013-10-01 |
PT2511262T (pt) | 2017-03-30 |
PL1806338T3 (pl) | 2016-07-29 |
BRPI0516337A (pt) | 2008-04-29 |
EP2511262A1 (en) | 2012-10-17 |
WO2006041019A1 (ja) | 2006-04-20 |
EP1806338A1 (en) | 2007-07-11 |
CA2583846A1 (en) | 2006-04-20 |
CN101072752A (zh) | 2007-11-14 |
AU2005292984A1 (en) | 2006-04-20 |
CN101880250A (zh) | 2010-11-10 |
JPWO2006041019A1 (ja) | 2008-05-15 |
KR20070073895A (ko) | 2007-07-10 |
AU2005292984B2 (en) | 2011-01-20 |
EP1806338B1 (en) | 2016-01-20 |
RU2007117372A (ru) | 2008-11-20 |
CN101880250B (zh) | 2013-04-03 |
ES2615498T3 (es) | 2017-06-07 |
EP2511262B1 (en) | 2017-02-01 |
US20080207941A1 (en) | 2008-08-28 |
RU2376285C2 (ru) | 2009-12-20 |
KR101181090B1 (ko) | 2012-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2563034T3 (es) | Procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol e hidratos del mismo, e intermedios para la producción de los mismos | |
JPH0660158B2 (ja) | 3つの置換基を有する安息香酸中間体 | |
TW201345880A (zh) | 烷基化芳香族醯胺衍生物之製造方法 | |
JP2005536484A (ja) | 光学活性(r)−アリールオキシプロピオン酸エステル誘導体の製造方法 | |
US20070112194A1 (en) | Process for preparing nitrooxyalkyl substituted esters of carboxylic acids, intermediates useful in said process and preparation thereof | |
CN101585778B (zh) | 一种普瑞巴林制备方法 | |
TW201504215A (zh) | 嗒□化合物之製造方法 | |
JP4922157B2 (ja) | ベンゾオキサチエピンの合成方法とその中間体 | |
JP2006232757A (ja) | フェノキシエチルハライド及びその誘導体の製造法 | |
JP2003327580A (ja) | 2−(置換ベンゾイル)チアジン誘導体、その製造方法及び除草剤 | |
JP4929717B2 (ja) | N,n’−ジアルコキシ−n,n’−ジアルキルオキサミドの製法 | |
KR20060123575A (ko) | 술포닐옥시 유도체 | |
JP4518065B2 (ja) | 新規ジアルコキシアミドオキシム誘導体及びその製法 | |
KR100597259B1 (ko) | 광학활성 (r)-2-페녹시프로피온산 유도체의 제조방법 | |
JP4518066B2 (ja) | ジアルコキシニトリル誘導体及びその製法 | |
JP5568137B2 (ja) | 含フッ素カルバマート基を有するアミノ酸アミド誘導体の製造方法、その製造中間体、及びエチレンジアミン誘導体の製造方法 | |
JP4194984B2 (ja) | フェニルナフチルイミダゾール化合物 | |
JP4524424B2 (ja) | 新規光学活性ジアミノホスフィンオキシド及びその製造方法、ジアミノホスフィンオキシド−パラジウム錯体並びにそれを用いた不斉4級炭素構築方法 | |
JP2006321788A (ja) | ニコチン酸誘導体又はその塩の製造方法 | |
JP2011068693A (ja) | 反応活性な基を有する新規なビフェニル化合物 | |
JP2005325026A (ja) | フェノキシエチルハライド及びその誘導体の製造方法 | |
KR20070086762A (ko) | 티오카르바메이트 유도체의 제조방법 | |
JP2007070362A (ja) | 2−(5−クロロ−2−ニトロフェニル)−2−置換酢酸エステル誘導体の製造法 | |
JPH08143539A (ja) | アニリド誘導体およびその製造法 | |
JPH05294931A (ja) | 新規中間体及び2−クロロ−5−(アミノメチル)ピリジンの製造方法 |